If approved in the European Union, Fruquintinib will be the first novel targeted therapy for Metastatic Colorectal Cancer regardless of biomarker status in over a decade
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
The company will closely work with the USFDA to address and respond to the observations in an expeditious manner
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
Approval from Colombia's INVIMA will accelerate growth in Colombia, by registering our product and getting regular supplies
Open a printable version of this pageEmail the URL of this page to a friend
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy
Tacrolimus is an immunosuppressant used in the treatment of organ transplant patients
Subscribe To Our Newsletter & Stay Updated
